Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript

Pacific Biosciences of California (PacBio) reported Q3 2025 revenue of $38.4 million, slightly below expectations due to fewer Vega shipments and lower Revio ASPs from strategic placements, yet consumable revenue reached a record $21.3 million, boosting non-GAAP gross margins to 42%. The company narrowed its full-year 2025 revenue guidance to $155-$160 million but projects 10% sequential growth for Q4. Key developments include regulatory approval for the Sequel II CNDx system in China, expanding clinical applications with the PureTarget portfolio, and the upcoming SPRQ-Nx chemistry featuring multi-use SMRT Cells, which is expected to dramatically lower sequencing costs to under $300 per genome and improve gross margins, aligning with PacBio's goal to achieve cash flow breakeven by late 2027.

Analysis

Pacific Biosciences reported Q3 2025 revenue of $38.4 million, slightly below expectations due to fewer Vega shipments and lower Revio ASPs from strategic placements. However, record consumable revenue of $21.3 million, up 15% year-over-year, drove non-GAAP gross margin to 42%, its highest since 2022. This reflects a favorable product mix and improved manufacturing efficiencies.

The company narrowed its full-year 2025 revenue guidance to $155-$160 million but projects 10% sequential growth for Q4, driven by increased instrument placements and consumable strength. Key advancements include the Class III Medical Device Registration for the Sequel II CNDx system in China, a global first for a clinical-grade long-read sequencer. The new SPRQ-Nx chemistry, with multi-use SMRT Cells, is expected to dramatically lower sequencing costs and improve gross margins, boosting market penetration.

PacBio reduced Q3 cash burn to $16 million, projecting a full-year 2025 burn of $115 million, a $70 million improvement over 2024. The company targets cash flow breakeven by late 2027, supported by current cash reserves of $298.7 million. This financial discipline, clinical expansion, and product innovation underpin long-term growth despite regional funding challenges.

Key Decisions for Investors

• Monitor the rollout and adoption rate of the new SPRQ-Nx chemistry, as its success is crucial for market penetration and gross margin expansion.
• Evaluate the sustainability of consumable revenue growth and Revio pull-through, particularly as strategic clinical applications and large-scale studies expand.
• Assess the company's progress towards cash flow breakeven by late 2027, paying close attention to cash burn reduction and overall financial discipline.
• Observe the impact of the China regulatory approval and PureTarget portfolio on clinical market expansion and revenue diversification.